The Clinical Significance of Mutations in Metastatic Oral Mucosal Melanoma in China

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 16

PMID 29137292

Citations 4

Authors

Xuhui Ma

Yunteng Wu

Tian Zhang

Hao Song

Houyu Jv

Wei Guo

Guoxin Ren

Affiliations

Soon will be listed here.

Abstract

mutations are frequently detected in mucosal melanomas, but their clinical significance in metastatic oral mucosal melanomas (OMM) remains unclear. The main purpose of this study was to investigate the clinical and pathological features of metastatic OMMs with mutations and the efficiency of the tyrosine kinase inhibitor imatinib in treating metastatic OMMs. We found thatresidual primary lesion and neck lymph nodes could act as independent prognostic factors in metastatic OMM patients. mutations were detected in 22 out of 139 (15.8%) metastatic OMM patients. Under chemotherapy, the overall survival (OS) of mutant patients was significantly shorter than that of wild-type patients. The Ki67 expression was significantly higher in mutant patients than in wild-type patients. In distant metastatic OMM patients with mutations, the treatment with c-Kit inhibitor resulted in a better OS. In conclusion, residual primary lesion, cervical lymph nodes and mutations act as adverse prognostic factors of metastatic OMMs. The Kit inhibitor imatinib could benefit metastatic OMM patients with mutations.

Citing Articles

Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.

Usta S, Uchihashi T, Kodama S, Kurioka K, Inubushi T, Shimooka T Int J Mol Sci. 2023; 24(24).

PMID: 38139110 PMC: 10743423. DOI: 10.3390/ijms242417282.

Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma.

Brocca G, Poncina B, Sammarco A, Cavicchioli L, Castagnaro M Animals (Basel). 2020; 10(12).

PMID: 33321993 PMC: 7764140. DOI: 10.3390/ani10122370.

Current Molecular Markers of Melanoma and Treatment Targets.

Yang K, Oak A, Slominski R, Brozyna A, Slominski A Int J Mol Sci. 2020; 21(10).

PMID: 32429485 PMC: 7278971. DOI: 10.3390/ijms21103535.

The mutational landscape of mucosal melanoma.

Nassar K, Tan A Semin Cancer Biol. 2019; 61:139-148.

PMID: 31655118 PMC: 7078020. DOI: 10.1016/j.semcancer.2019.09.013.

References

Omholt K, Grafstrom E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding B . KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res. 2011; 17(12):3933-42. DOI: 10.1158/1078-0432.CCR-10-2917. View

Haiducu M, Hinek A, Astanehe A, Lee T, Kalia S . Extracutaneous melanoma epidemiology in British Columbia. Melanoma Res. 2014; 24(4):377-80. DOI: 10.1097/CMR.0000000000000075. View

Keller D, Thomay A, Gaughan J, Olszanski A, Wu H, Berger A . Outcomes in patients with mucosal melanomas. J Surg Oncol. 2013; 108(8):516-20. DOI: 10.1002/jso.23445. View

Woodman S, Davies M . Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010; 80(5):568-74. PMC: 3935736. DOI: 10.1016/j.bcp.2010.04.032. View

Todd J, Scurr L, Becker T, Kefford R, Rizos H . The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene. 2012; 33(2):236-45. DOI: 10.1038/onc.2012.562. View

Carvajal R, Antonescu C, Wolchok J, Chapman P, Roman R, Teitcher J . KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305(22):2327-34. PMC: 3986039. DOI: 10.1001/jama.2011.746. View

Beadling C, Jacobson-Dunlop E, Hodi F, Le C, Warrick A, Patterson J . KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008; 14(21):6821-8. DOI: 10.1158/1078-0432.CCR-08-0575. View

Smalley K, Sondak V, Weber J . c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009; 24(5):643-50. DOI: 10.14670/HH-24.643. View

Patel P, Suciu S, Mortier L, Kruit W, Robert C, Schadendorf D . Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011; 47(10):1476-83. DOI: 10.1016/j.ejca.2011.04.030. View

10.

Lennartsson J, Ronnstrand L . Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012; 92(4):1619-49. DOI: 10.1152/physrev.00046.2011. View

11.

Owens B . Melanoma. Nature. 2014; 515(7527):S109. DOI: 10.1038/515S109a. View

12.

Hodi F, Friedlander P, Corless C, Heinrich M, Mac Rae S, Kruse A . Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26(12):2046-51. DOI: 10.1200/JCO.2007.14.0707. View

13.

Song H, Wu Y, Ren G, Guo W, Wang L . Prognostic factors of oral mucosal melanoma: histopathological analysis in a retrospective cohort of 82 cases. Histopathology. 2015; 67(4):548-56. DOI: 10.1111/his.12692. View

14.

Chapman P, Einhorn L, Meyers M, Saxman S, Destro A, Panageas K . Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17(9):2745-51. DOI: 10.1200/JCO.1999.17.9.2745. View

15.

Houghton A, Polsky D . Focus on melanoma. Cancer Cell. 2002; 2(4):275-8. DOI: 10.1016/s1535-6108(02)00161-7. View

16.

Ali S, Ali S . Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene. 2007; 401(1-2):38-45. DOI: 10.1016/j.gene.2007.06.017. View

17.

Jiang X, Zhou J, Yuen N, Corless C, Heinrich M, Fletcher J . Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008; 14(23):7726-32. DOI: 10.1158/1078-0432.CCR-08-1144. View

18.

Yarden Y, Kuang W, Coussens L, MUNEMITSU S, Dull T, Chen E . Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987; 6(11):3341-51. PMC: 553789. DOI: 10.1002/j.1460-2075.1987.tb02655.x. View

19.

Curtin J, Busam K, Pinkel D, Bastian B . Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26):4340-6. DOI: 10.1200/JCO.2006.06.2984. View

20.

Demetri G, Reichardt P, Kang Y, Blay J, Rutkowski P, Gelderblom H . Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):295-302. PMC: 3819942. DOI: 10.1016/S0140-6736(12)61857-1. View